UBS raised its target for RXO from $23.00 to $30.25, but kept a neutral rating. The higher target is favorable, but the unchanged rating gives no clear reason to change RXO’s business outlook.
A higher target suggests UBS sees more room for RXO shares than before. But the firm still rates RXO neutral, and the story reports no change in sales, costs, or company plans. That leaves the company outlook unchanged.
Follow RXO, Inc. (RXO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RXO